It has also been demonstrated that tocilizumab has anticancer potency via apoptosis induction as an agonistic IL-6R regulator and may be utilized as a new target molecule for non-small-cell lung cancer (NSCLC) [2]. The gene discussed is IL6R; the disease is non-small cell lung carcinoma.